Mingjie Lin

and 9 more

Background Previous research indicates disparities in atrial fibrillation (AF) recurrence and complications following catheter ablation in women; however, long-term outcomes based on gender remain underexplored. Objective This study evaluated the long-term rates of AF recurrence and major adverse cardiovascular and cerebrovascular events (MACCE) following catheter ablation, investigating gender-related risk factors to inform clinical practice improvement. Methods We conducted a retrospective analysis using data from a prospectively observational registry of AF ablation procedures at our institution from 2015 to 2020. Patients were followed up for MACCE and AF recurrence. The risk factors of AF recurrence and MACCE were further explored. Results The study cohort consisted of 2,293 patients, including 1,441 males and 852 females, and had an average follow-up duration of 50.36 months. After catheter ablation, females exhibited a notably higher rate of recurrence compared to males, with a hazard ratio of 1.305 and a 95% confidence interval ranging from 1.101 to 1.547, which was statistically significant (p=0.0014). Gender differences in AF recurrence persisted regardless of early versus late intervention (both p<0.05). No significant difference in MACCE rates was observed between genders. Independent risk factors for AF recurrence included female gender, diabetes, left atrial diameter ≥40 mm. Conclusions Gender differences significantly impact the long-term outcomes of AF recurrence, but not MACCE rates post-catheter ablation. The study highlights the necessity to integrate gender considerations into AF management strategies.

Mingjie Lin

and 3 more

Aims: To assess the effect of oral anticoagulant (OAC) administration on incidence of dementia in patients with atrial fibrillation (AF) with Systematic review and meta-analysis in according with the Preferred Reporting Items for Systematic Review and Meta-analysis Protocols. Methods: We systematically searched the electronic databases including Pubmed, Embase, Cochrane library, and ClinicalTrails.gov for relevant articles. The primary outcome was the incidence of dementia. The adjusted risk ratio (RR), odds ratio, or hazard ratio were extracted and pooled by the random-effects models. Subgroup analysis was performed according to the setting observational window. Risk of bias was assessed using the Newcastle-Ottawa Scale, while publication bias was assessed by the Begg’s and Egger’s tests. Results: Nine studies included in this review (2 prospective and 7 retrospective observational studies, including 613,920 patients). The results presented the significant association between OAC therapy and the reduced risk of dementia compared with no treatment (RR [95%CI] =0.72 [0.60, 0.86], I2=97.2%; P =0.000). In the subgroup analysis, the pooled RR became statistically non-significant (including four studies, RR [95%CI] =0.75 [0.51, 1.10], I2=98.8%; P =0.000). There is no significant risk of bias and publication bias. Conclusions: This study indicated the protective effect of OAC therapy for dementia in patients with AF. However, the results are limited because of high heterogeneity, inconsistent direction of effect in subgroup analysis. Further prospective well-designed study is needed with longer follow-up duration in younger patients.

Rina Sha

and 3 more

Background: Although epicardial adipose tissue (EAT) has been proved be associated with atrial fibrillation (AF) and post-ablation AF recurrence, the relationship between EAT and AF after cardiac surgery (AFACS) is not evident, yet. Objective: In the study, we aim to perform a systematic review and meta-analysis to assess the association between EAT and AFACS and whether it is independent of the measurement methods. Methods: Systematic reach was implemented until May, 30, 2020, which “atrial fibrillation” and “epicardial adipose tissue” were as the main items in electronic databases. Analysis was stratified by EAT measurement methods into three pooled meta-analyses on 1) total EAT volume, 2) left atrium (LA)-EAT volume and 3) EAT thickness between two groups with and without AFACS, estimating standardized mean difference (SMD) with a random effect model. Results: Eight articles with ten studies (546 patients) were included. Accordingly, the results of meta-analysis showed that EAT was higher in AFACS subjects, regardless of the methods of EAT measurement.[ total EAT volume: SMD = 0.56 ml; 95% confidence interval (CI) = 0.56-1.10ml, I2 = 0.90, P=0.04; EAT thickness: SMD = 0.85mm; 95% CI = 0.04-1.65mm, I2 = 0.90, P=0.04; LA-EAT volume: SMD = 0.57ml, 95% CI = 0.23-0.92ml, I2 = 0.00, P=0.001.] And there was no evidence of publication bias. Conclusion: EAT may be a potential marker and therapeutic target for AFACS. However, larger scale studies are still required, and evaluation is needed to for further estimation.

Bing Rong

and 9 more